GLP-1 treatments
Wegovy treatment in Romania
Semaglutide for weight loss — online consultation, eligibility assessment and prescription with Dr. Petrache.
What is Wegovy?
Wegovy contains semaglutide, a GLP-1 receptor agonist. In the European Union, it is authorised for weight management in eligible people, alongside a reduced-calorie diet and physical activity. Administration information depends on the prescribed formulation.
Semaglutide was originally developed by Novo Nordisk to treat type 2 diabetes (under the name Ozempic, at lower doses). Clinical studies showed that at higher doses, semaglutide produces significant weight loss even in patients without diabetes, leading to Wegovy’s approval as a dedicated treatment for obesity and overweight.
Unlike dietary supplements or restrictive diets, Wegovy acts at a physiological level, changing the body’s hunger and satiety signals. It is a medically prescribed and monitored treatment, not a product that can be bought without a prescription.
How semaglutide works
Semaglutide acts on the GLP-1 receptor and influences the regulation of appetite, food intake and blood glucose. Treatment response and tolerability vary from person to person.
Consult the official EMA information for Wegovy. The prescribed formulation and dose must be discussed with the doctor; average study results are not a promise of weight loss.
Who can take Wegovy?
Wegovy is indicated for adults who meet at least one of the following eligibility criteria:
BMI ≥ 30 kg/m²
People with obesity, regardless of other conditions. BMI (Body Mass Index) is calculated by dividing weight (kg) by height squared (m²).
BMI ≥ 27 kg/m² + comorbidities
People with overweight who have at least one weight-related condition: type 2 diabetes, high blood pressure, dyslipidaemia, sleep apnoea or cardiovascular disease.
What to discuss before treatment
During the online consultation, Dr. Petrache will assess your health, complete medical history and the medicines you take to determine whether Wegovy is right for you. This personalised assessment is essential for treatment safety.
How the online consultation for Wegovy works
The consultation begins with a medical assessment. Any prescription depends on the indication and each patient’s situation.
Online booking
Choose and pay for the online nutrition consultation. Once payment is confirmed, select an available calendar slot. The appointment is subsequently confirmed by the doctor; check your email and the status in your account.
Video consultation with Dr. Petrache
During the consultation, Dr. Petrache will review your medical history, assess your eligibility for Wegovy, discuss the benefits and risks of treatment and answer all your questions.
Prescription and treatment plan
If you are eligible, you will receive a medical prescription to present at the pharmacy, together with a dosing plan, administration instructions and nutritional recommendations.
How Wegovy administration is determined
The dose, gradual escalation and duration of Wegovy treatment are determined by the doctor according to the official information for the prescribed formulation and the individual response. A general schedule found online does not replace a prescription.
Do not change the dose or restart treatment after a break without your doctor’s recommendation. For a missed dose, follow the instructions in the leaflet for your exact medicine and ask your doctor or pharmacist for advice.
Side effects and warning signs
Wegovy may cause digestive reactions such as nausea, diarrhoea, vomiting, constipation and abdominal pain. Frequency and severity vary with the medicine, population and dose; consult the current leaflet for the complete list.
Persistent or intense symptoms, repeated vomiting, inability to stay hydrated and severe abdominal pain require medical assessment. Seek immediate help for sudden loss or rapid worsening of vision. For breathing difficulties, facial swelling or other signs of an emergency, call 112.
Wegovy and Mounjaro: discussing the choice
Wegovy contains semaglutide, while Mounjaro contains tirzepatide. Both are authorised in the European Union for weight management in eligible people, alongside a reduced-calorie diet and physical activity.
Percentages from different studies do not predict individual results. The choice depends on the indication, medical history, tolerability and concomitant treatments. The doctor explains the options suitable for you.
For comparative data and their limitations, see the Wegovy vs Mounjaro guide.
Why choose Clinica Virtuală for a Wegovy prescription
Clinica Virtuală Dr. Petrache offers a comprehensive, safe and convenient medical experience for patients who want to start Wegovy treatment:
Experienced doctor
Dr. Petrache, a doctor in diabetology and nutrition, reviews your medical history and discusses treatment options during the consultation.
A full consultation, not just a prescription
Every patient receives a comprehensive medical assessment, not just a prescription. Dr. Petrache reviews the full medical context before recommending a treatment.
Maximum convenience
The consultation takes place entirely online, wherever you are. There is no need to travel to a practice or wait in a queue.
Long-term monitoring
Dr. Petrache provides regular monitoring of your progress, dose adjustments and management of any side effects throughout treatment.
Transparent prices
All costs are clearly displayed on the website, with no surprises. You know exactly what you will pay for the consultation before booking.
Frequently asked questions about Wegovy
Is Wegovy available in Romania?
Wegovy is authorised in the European Union. Check with the pharmacy for the availability of the prescribed formulation and dose in Romania; authorisation does not guarantee stock availability.
How much does Wegovy treatment cost?
The medicine’s price depends on the formulation, dose and chosen pharmacy and is checked when it is dispensed. The consultation is a separate service; its price and inclusions are shown on the online nutrition consultation page.
How quickly will I lose weight with Wegovy?
The response varies from person to person. Average study results depend on the population, dose and duration and do not guarantee the number of kilograms lost or the rate of weight loss. Goals and monitoring are agreed with the doctor.
Can I take Wegovy if I do not have diabetes?
Yes. Wegovy is specifically approved for weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity, whether or not they have diabetes.
What happens if I stop Wegovy treatment?
Studies show that most patients regain some of the weight lost after stopping treatment. Dr. Petrache therefore recommends adopting healthy eating habits during treatment to maintain results over the long term.
Can I take Wegovy with other medicines?
Wegovy may interact with certain medicines, including insulin and sulfonylureas. During the online consultation, Dr. Petrache will review the full list of medicines you take to check compatibility and adjust doses if necessary.
Do I need a prescription for Wegovy?
Wegovy is a prescription medicine. The consultation provides an assessment; a prescription is issued only if the doctor determines that treatment is indicated. The medicine is dispensed at a pharmacy under the applicable conditions.
How is the Wegovy injection administered?
Administer it according to the prescription and the instructions for the device dispensed. Ask your doctor or pharmacist to explain the technique; do not assume that all pens are prepared and used in the same way.
Are you ready to start Wegovy treatment?
Request an online consultation with Dr. Petrache for an assessment and discussion of your options. A prescription is issued only if medically indicated.
Book a consultationOfficial information about Wegovy
Indications, precautions and administration should be checked in the official medicine information and discussed with the doctor. Do not change the dose based on information on this page. Authorisation in the European Union does not guarantee availability in pharmacies in Romania.
European Medicines Agency — Wegovy (in English)